The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma

被引:27
|
作者
Schmitz, Susanne [1 ]
Maguire, Aine [2 ,3 ]
Morris, James [4 ]
Ruggeri, Kai [3 ,14 ]
Haller, Elisa [5 ]
Kuhn, Isla [6 ]
Leahy, Joy [7 ]
Homer, Natalia [4 ]
Khan, Ayesha [8 ]
Bowden, Jack [9 ]
Buchanan, Vanessa [4 ]
O'Dwyer, Michael [10 ]
Cook, Gordon [11 ,12 ]
Walsh, Cathal [13 ]
机构
[1] Luxembourg Inst Hlth, Dept Populat Hlth, Strassen, Luxembourg
[2] Trinity Coll Dublin, Dept Psychiat, Dublin, Ireland
[3] Univ Cambridge, Dept Psychol, Cambridge, England
[4] Cogentia Healthcare Consulting, Cambridge, England
[5] Univ Zurich, Dept Psychol, Zurich, Switzerland
[6] Univ Cambridge, Univ Lib Med Lib, Cambridge, England
[7] Trinity Coll Dublin, Dept Comp Sci & Stat, Dublin, Ireland
[8] Univ Exeter, Exeter, Devon, England
[9] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England
[10] NUI Galway, Dept Med, Galway, Ireland
[11] St James Univ Hosp, Haematol & Myeloma Studies, Leeds, W Yorkshire, England
[12] St James Univ Hosp, NIHR MIC DEL, Leeds, W Yorkshire, England
[13] Univ Limerick, Hlth Res Inst, Limerick, Ireland
[14] Columbia Univ, Dept Hlth Policy & Management, Mailman Sch Publ Hlth, New York, NY USA
来源
BMC MEDICAL RESEARCH METHODOLOGY | 2018年 / 18卷
关键词
Network meta-analysis; Single armed studies; Evidence synthesis; Relapsed or refractory myeloma; LENALIDOMIDE PLUS DEXAMETHASONE; ADJUSTED INDIRECT COMPARISONS; MIXED TREATMENT COMPARISONS; LOW-DOSE DEXAMETHASONE; RANDOMIZED PHASE-III; PROPENSITY SCORE; REFRACTORY MYELOMA; TREATMENT OUTCOMES; BORTEZOMIB; THERAPY;
D O I
10.1186/s12874-018-0509-7
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Network meta-analysis (NMA) allows for the estimation of comparative effectiveness of treatments that have not been studied in head-to-head trials; however, relative treatment effects for all interventions can only be derived where available evidence forms a connected network. Head-to-head evidence is limited in many disease areas, regularly resulting in disconnected evidence structures where a large number of treatments are available. This is also the case in the evidence of treatments for relapsed or refractory multiple myeloma. Methods: Randomised controlled trials (RCTs) identified in a systematic literature review form two disconnected evidence networks. Standard Bayesian NMA models are fitted to obtain estimates of relative effects within each network. Observational evidence was identified to fill the evidence gap. Single armed trials are matched to act as each other's control group based on a distance metric derived from covariate information. Uncertainty resulting from including this evidence is incorporated by analysing the space of possible matches. Results: Twenty five randomised controlled trials form two disconnected evidence networks; 12 single armed observational studies are considered for bridging between the networks. Five matches are selected to bridge between the networks. While significant variation in the ranking is observed, daratumumab in combination with dexamethasone and either lenalidomide or bortezomib, as well as triple therapy of carfilzomib, ixazomib and elozumatab, in combination with lenalidomide and dexamethasone, show the highest effects on progression free survival, on average. Conclusions: The analysis shows how observational data can be used to fill gaps in the existing networks of RCT evidence; allowing for the indirect comparison of a large number of treatments, which could not be compared otherwise. Additional uncertainty is accounted for by scenario analyses reducing the risk of over confidence in interpretation of results.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma
    Susanne Schmitz
    Áine Maguire
    James Morris
    Kai Ruggeri
    Elisa Haller
    Isla Kuhn
    Joy Leahy
    Natalia Homer
    Ayesha Khan
    Jack Bowden
    Vanessa Buchanan
    Michael O’Dwyer
    Gordon Cook
    Cathal Walsh
    BMC Medical Research Methodology, 18
  • [2] SINGLE ARMED OBSERVATIONAL DATA TO CLOSING THE GAP IN OTHERWISE DISCONNECTED EVIDENCE NETWORKS
    Schmitz, S.
    Maguire, A.
    Morris, J.
    Walsh, C.
    VALUE IN HEALTH, 2017, 20 (09) : A757 - A757
  • [3] BRIDGING THE GAP IN DISCONNECTED NETWORKS IN NETWORK META-ANALYSIS (NMA)
    Sharma, A.
    Pandey, S.
    Pandey, K.
    Singh, B.
    VALUE IN HEALTH, 2023, 26 (06) : S289 - S289
  • [4] A Theoretical Investigation of How Evidence Flows in Bayesian Network Meta-Analysis of Disconnected Networks
    Beliveau, Audrey
    Gustafson, Paul
    BAYESIAN ANALYSIS, 2021, 16 (03): : 803 - 823
  • [5] Bisphosphonates in multiple myeloma: a network meta-analysis
    Mhaskar, Rahul
    Redzepovic, Jasmina
    Wheatley, Keith
    Camara Clark, Otavio Augusto
    Miladinovic, Branko
    Glasmacher, Axel
    Kumar, Ambuj
    Djulbegovic, Benjamin
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (05):
  • [6] Network Meta-analysis on Disconnected Evidence Networks When Only Aggregate Data Are Available: Modified Methods to Include Disconnected Trials and Single-Arm Studies while Minimizing Bias
    Thom, Howard
    Leahy, Joy
    Jansen, Jeroen P.
    MEDICAL DECISION MAKING, 2022, 42 (07) : 906 - 922
  • [7] Bisphosphonates in multiple myeloma: an updated network meta-analysis
    Mhaskar, Rahul
    Kumar, Ambuj
    Miladinovic, Branko
    Djulbegovic, Benjamin
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (12):
  • [8] Maintenance Therapies for Multiple Myeloma (MM): A Network Meta-Analysis
    Mahony, Helen
    Kumar, Ambuj
    Mhaskar, Rahul
    Miladinovic, Branko
    Wheatley, Keith
    Djulbegovic, Benjamin
    BLOOD, 2012, 120 (21)
  • [9] Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis
    Luo, Xian-Wu
    Du, Xue-Qing
    Li, Jie-Li
    Liu, Xiao-Ping
    Meng, Xiang-Yu
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 2817 - 2823
  • [10] Use of daratumumab in high risk multiple myeloma: A meta-analysis
    Premkumar, Vikram
    Pan, Samuel
    Lentzsch, Suzanne
    Bhutani, Divaya
    EJHAEM, 2020, 1 (01): : 267 - 271